GLP-1 access in Vietnam and the Philippines

TL;DR

• Both markets treat GLP-1s as prescription-only, and in both the diabetes registration is far better established than the obesity registration - the single fact most readers get wrong.
• A diabetes registration and a weight-management registration are different approvals - different dossiers, brand names, presentations and labelled indications, not one product with two uses.
• Vietnam's DAV has registered injectable semaglutide under a diabetes label - registration no. 570410174600, decision 803/QĐ-QLD, dated 7 December 2024; no weight-management registration could be confirmed as of August 2026.
• FDA Philippines registered injectable semaglutide for type 2 diabetes in 2022, with a weight-management product reported approved and marketed from late 2025 - a status worth verifying directly against the FDA-PH register.
• PhilHealth does not cover GLP-1s for weight management, against an FNRI 2025 survey finding 44.5% of Filipino adults aged 20–59 obese, up from 39.8% in 2023.
• Falsified semaglutide is documented, not hypothetical - the WHO issued a Medical Product Alert in June 2024, and these injectables require a 2–8°C cold chain that informal sellers cannot demonstrate.

---

Educational content, not medical advice. This article contains no doses, schedules or protocols.

What is actually registered in each country, and by which regulator

Two regulators govern this question, and neither of them is the US FDA, the EMA, or whatever authority a reader's source material was quoting.

In Vietnam, the regulator is the Drug Administration of Vietnam (DAV) - Cục Quản lý Dược - an agency of the Ministry of Health. The DAV evaluates registration dossiers, and marketing authorisation is granted as a drug registration number (số đăng ký) issued under a numbered DAV decision (QĐ-QLD). A separate point that trips people up: registration and import authorisation are two different permissions in Vietnam. A product can be registered and still be constrained by whether a licensed importer has brought stock in.

In the Philippines, the regulator is the Food and Drug Administration Philippines (FDA-PH), an attached agency of the Department of Health. Marketing authorisation there takes the form of a Certificate of Product Registration (CPR) with an FDA registration number, and the licensing of importers and distributors is a separate track from the registration of the product itself.

The distinction that matters more than any of this, and the one this page exists to make, is between a diabetes registration and an obesity registration. They are not the same approval. Semaglutide registered for type 2 diabetes and semaglutide registered for chronic weight management are, regulatorily, different products with different dossiers - different brand names, different presentations, different labelled indications. A reader who has confirmed that "semaglutide is available here" has not confirmed that a weight-management product is available here. Almost every confused conversation on this topic starts at that exact point.

Here is the side-by-side, with the honest gaps left visible:

Every "not confirmed" in that table is a real research finding, not a placeholder. It means we could not locate a primary or reliably secondary source establishing the status as of August 2026 - and a page that guessed would be worse than a page with gaps in it.

Vietnam: the prescription pathway, availability, and what the current supply picture looks like

The clearest fact available for Vietnam is the one in the table: injectable semaglutide holds a DAV registration under a specific number and a specific decision, and its label is a diabetes label. The registered indication covers glycaemic control in adults with type 2 diabetes and reduction of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease. It is classified as a prescription medicine.

That has three practical consequences.

First, the legal route runs through a licensed prescriber. A prescription-only classification is not a formality in Vietnam any more than it is anywhere else. It means assessment, a prescription, and dispensing through licensed channels.

Second, a weight-management prescription in Vietnam is a different conversation from one in Malaysia or Singapore. Where a weight-management product is registered - as it is in several neighbouring markets - a clinician is prescribing within a labelled indication. Where only a diabetes-labelled product is registered, any weight-management use is a clinical decision made outside the registered indication, and the rules and professional norms governing that are a matter for Vietnamese medical regulation, not for a webpage. We did not verify Vietnam-specific guidance on off-label prescribing for weight management, and we are not going to characterise it.

Third, registration is not stock. A registration number establishes that a product may legally be sold; it does not establish that it is on a shelf this month. Availability in Vietnam is reported as uneven and concentrated in larger urban and international-standard facilities. We found no verified DAV shortage notification for GLP-1 products in Vietnam as of August 2026 - which is not the same as saying supply is uniform, only that we could not source an official constraint to report.

The Philippines: FDA-PH registration status and the private-clinic route

The Philippine picture is better documented in public sources, largely because the market is more openly commercial and better covered by domestic press.

Injectable semaglutide has been FDA-PH registered for type 2 diabetes since 2022. A weight-management semaglutide product is reported to have entered the Philippine market in late 2025 following local regulatory approval - this is the single most consequential difference between the two countries covered here, because it means the Philippines plausibly has a labelled weight-management route where Vietnam, as far as we could confirm, does not. It is also the claim on this page most in need of direct verification against the FDA-PH register before anyone acts on it.

The demand side is not speculative. The Food and Nutrition Research Institute's 2025 updating survey found 44.5% of Filipino adults aged 20–59 classified as obese, up from 39.8% in 2023, with the National Capital Region highest at 52.7%. Diabetes prevalence sits on a similar trajectory - roughly 4.3 million diagnosed cases as of 2021, with a substantial undiagnosed population on top, and projections into the mid-single-digit millions by 2045. That is a large population meeting the clinical criteria these medicines were approved for.

What it is not is a population that can pay for them. PhilHealth does not cover GLP-1 medicines for weight management. Private HMO coverage for the diabetes indication exists in some plans but typically requires pre-authorisation and documented laboratory evidence. For most Filipino patients, this is entirely out of pocket.

That combination - high clinical need, a functioning private-clinic sector, and no public reimbursement - is what produces the Philippine access pattern: a legitimate, registered, prescription route that is real but expensive, sitting next to a large informal market that is neither.

Price reality in both markets, with the caveats that belong on any figure

Every figure in this section is INDICATIVE and DATED. It reflects reporting available as of August 2026, it will move, and it should not be used to budget.

For the Philippines, the figures we could source, in Philippine pesos (PHP):

• Injectable semaglutide for diabetes: quoted at approximately PHP 7,560 per pen at licensed pharmacies.
• Weight-management semaglutide: reported as roughly double the per-unit cost of the diabetes product.
• Tirzepatide, where clinics carry it: monthly figures quoted in the range of PHP 12,000–20,000.

For Vietnam, in Vietnamese dong (VND): we could not source credible pricing from any non-commercial source, and we are not going to publish a number we cannot stand behind. The VND figures circulating online originate overwhelmingly from sellers, which makes them marketing rather than market data.

Here is why every one of those numbers - including the sourced ones - is unreliable in a specific and predictable way:

• Private-clinic mark-up. A pharmacy shelf price and a clinic price are different animals. Clinics price a service, not a box, and the spread between them can be large.
• Pack size and presentation differences. Quoted prices attach to different presentations. A "per pen" price and a "per month" price are not convertible without knowing what is in the pen and what regimen is assumed - and quoted monthly figures almost never state the assumption behind them. This page will not supply that assumption, because doing so would be a dosing statement.
• Import duties, distributor margin and channel. Both markets sit at the end of an import chain. Duties, distributor margin and cold-chain logistics are baked into the shelf price and vary by channel.
• Currency movement. These are dollar- or euro-denominated products sold in PHP and VND. A quote from six months ago has already moved.
• Whether a consultation is bundled. Some quoted prices include assessment, monitoring and follow-up; some are the medicine alone. Comparing a bundled price to an unbundled one and concluding one clinic is cheaper is the most common pricing error people make in both markets.
• Reimbursement status. In the Philippines, the absence of PhilHealth coverage for weight management means the sticker price is the price.

The honest summary: the Philippines has published prices you can partially triangulate; Vietnam does not. In both, a price quoted without the pack size, the channel and what is bundled into it is not information.

Why the grey market is larger where registration lags

There is a straightforward mechanism at work, and it is worth naming because it predicts where the risk concentrates.

Demand for these medicines is now largely driven by weight, not by diabetes. Where a market has a registered weight-management product, that demand has somewhere legal to go. Where a market has only a diabetes-registered product - or where the weight-management product is registered but priced beyond most of the population - demand does not disappear. It routes around the gap. That is the grey market: not a parallel version of the same thing, but a completely different risk profile wearing the same brand names.

Two 2026 developments make this materially more pressing across the region.

The semaglutide patent expired in several jurisdictions in March 2026, notably including India and China. Indian manufacturers launched generic semaglutide within days, at prices reported up to 70% below the originator, with a large number of additional products expected through the year. Chinese domestic generic production is expanding on a similar curve, and reported price collapses have extended to tirzepatide products on some online trading platforms.

Regulators noticed immediately. India's Ministry of Health issued guidance in April 2026 restricting GLP-1 prescribing to specified specialist categories - a response to exactly the risk this page is about. Commentary at the time flagged the obvious downstream consequence: cheap semaglutide originating in the region will reach Vietnam, the Philippines, Indonesia and Thailand, where regulatory capacity varies widely, private clinics operate under inconsistent oversight, and rapidly rising demand can outpace the legal framework.

Layered on top of that is a documented counterfeit problem that predates the generics wave. The World Health Organization issued a Medical Product Alert on falsified semaglutide in June 2024, and its Global Surveillance and Monitoring System has tracked falsified semaglutide reports across all regions since 2022, including reports in the Philippines. FDA-PH has echoed warnings on the same theme, attributing supply disruption in part to the surge in off-label weight-loss demand.

The specific hazard is not only "the vial might be fake." Injectable GLP-1s require cold-chain storage between 2°C and 8°C. A product that is entirely genuine but has spent a day at ambient temperature in a courier bag is not a cheaper version of the medicine - it is a syringe of something whose potency nobody can characterise. Social-media sellers, online marketplaces and informal group-buys cannot demonstrate cold chain, and that failure alone is sufficient to make the product useless regardless of what is in it.

What "imported for personal use" does and does not permit

This section is deliberately short, and it is not a route map.

Most jurisdictions, including both covered here, draw some distinction between commercial importation - which requires product registration, importer licensing and import authorisation - and a narrow allowance for individuals bringing in medicine for their own use. People read that second category as a loophole. At a legal-concept level, it is not, and here is why.

A personal-use allowance is an exemption from commercial import licensing. It is not an exemption from prescription-only status. A medicine that requires a prescription still requires a prescription. The allowance concerns who may bring goods across a border without a trading licence; it says nothing about whether a person is entitled to possess or use a prescription-only medicine without one.

Three further limits belong on any reading of it:

• It does not permit onward supply. Personal use means personal. Selling, sharing or distributing an imported prescription medicine is a separate and more serious matter in both markets.
• It does not confer product validity. Nothing about a personal-import allowance verifies that a product is genuine, correctly labelled, or that its cold chain held. The allowance is a customs concept, not a quality assurance.
• It is conditional and enforceable. Allowances are narrowly bounded, typically require documentation, and customs authorities can and do seize products. Being wrong about the boundary is the traveller's problem, not the seller's.

We have deliberately not published quantity thresholds, documentation requirements or procedures for either country. They are the sort of detail that changes without notice, they differ by product class, and publishing them would convert a legal explainer into an instruction sheet. Anyone with a genuine cross-border continuity-of-care question - someone who is legitimately prescribed a medicine in one country and travels to another - should raise it with their prescribing clinician and check the current position with the DAV or FDA-PH and the relevant customs authority. That is the only correct answer to this question, and it is not a evasive one.

Choosing a clinic in either market

This page names no clinics, and would not be more useful if it did. What is useful is the set of questions that separates a clinic running a medical service from one running a retail counter. The same questions work in Ho Chi Minh City, Hanoi, Manila or Cebu.

• "Is this specific product registered in this country, and for which indication?" Ask for the registration number - the DAV số đăng ký or the FDA-PH registration - and check it against the regulator yourself. A clinic that cannot or will not produce it has answered the question.
• "Am I being prescribed a diabetes-registered product or a weight-management-registered product, and which am I being treated for?" If those two answers do not line up, you should understand exactly why before agreeing to anything.
• "Who is prescribing, and are they licensed here?" A named, locally licensed clinician who has taken a history - not a coordinator, not a consultant reachable only by message.
• "What assessment happens before, and what monitoring happens after?" Baseline history, relevant investigations, and scheduled review. A service that dispenses on the first contact with no assessment is a supply chain, not a clinic.
• "What happens if I have a side effect at 2am?" This is the question that most reliably exposes a retail operation. There should be a named point of contact, a defined escalation path, and a clinician who takes responsibility. "Message us during office hours" is an answer, and it is the wrong one.
• "How is the cold chain handled - in your storage and in my hands?" Ask how the product is stored on site and what you are told to do with it.
• "What is included in the price?" Assessment, monitoring, follow-up and product should be itemised. This is also how you find out whether a cheaper quote is actually cheaper.

The same framework, in more depth, is in how to choose a peptide clinic. The regional regulatory context sits in peptide legality across Southeast Asia.

Frequently asked questions

Is Ozempic legal in the Philippines? Injectable semaglutide for type 2 diabetes has been FDA-PH registered since 2022, and it is a prescription-only medicine. Legal is not the same as unrestricted: it requires a prescription from a licensed clinician following assessment, and it should be obtained through FDA-registered channels. Buying from social-media sellers or online marketplaces is neither legal supply nor verifiable product, and PhilHealth does not cover it for weight management.

Is Wegovy approved in Vietnam? We could not confirm a Wegovy registration in Vietnam as of August 2026. What we could confirm is that injectable semaglutide is registered with the DAV under a diabetes label, with a specific registration number and decision date. Those are different approvals. If a clinic or seller tells you a weight-management semaglutide product is registered in Vietnam, ask for the registration number and check it against the DAV before believing it - and if the answer changes after this page was written, the DAV will know before we do.

Can I get a GLP-1 in Manila or Ho Chi Minh City as a foreign visitor? Both markets require a prescription from a locally licensed clinician following assessment, and that applies to visitors as much as to residents. The harder questions are the ones people skip: who monitors you after you leave, how you continue treatment at home, and how a temperature-sensitive injectable travels. Starting a chronic therapy abroad without a continuity plan is a poor idea in any market, and it is covered in more detail in GLP-1 access in Singapore, Thailand and Indonesia.

Why is the pricing information so vague? Because the credible pricing is thin and the confident pricing is mostly marketing. The Philippines has partially triangulable published figures; Vietnam's publicly visible prices come overwhelmingly from sellers. On top of that, quoted prices differ by pack size, channel, clinic mark-up, import cost, currency movement and whether consultation and monitoring are bundled in. A number without those five things attached is not a price, and we would rather publish the caveats than a figure that reads as authoritative and is not.

Related reading

• GLP-1s in Malaysia: the rules, the brands, and how to verify - the most developed regulatory picture in the region, and a useful benchmark for what a mature registration and verification regime looks like
• GLP-1 access in Singapore, Thailand and Indonesia - three more regulators, plus the medical-tourism caveats
• Peptide legality across Southeast Asia - the wider regulatory map beyond GLP-1s
• How to choose a peptide clinic - the questions, red flags and checklist in full

Part of GLP-1s & Peptides in Southeast Asia: The Access & Regulation Guide.

Educational content, not medical advice, and not a substitute for guidance from the Drug Administration of Vietnam or FDA Philippines. Registration status changes, and several statuses on this page are explicitly marked unconfirmed - verify the current position with the national regulator before acting on anything here. GLP-1s are prescription medicines in both markets and require individual clinical assessment. Nothing on this page describes how to obtain a prescription-only medicine without a prescription, and nothing on it should be read as encouragement to import, source or self-supply. No doses, schedules or protocols appear. Claims for the Malaysian market are subject to MAB requirements.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore semaglutide.

References

• Drug Administration of Vietnam (DAV / Cục Quản lý Dược), Ministry of Health - national medicines regulator; issues drug registration numbers (số đăng ký) under numbered decisions (QĐ-QLD); commercial import authorisation is a separate permission from registration.
• Vietnamese product registration record for injectable semaglutide (Ozempic): registration no. 570410174600; decision 803/QĐ-QLD; dated 7 December 2024 (registration round 52); manufacturer Novo Nordisk A/S; classified as a prescription medicine; labelled indications type 2 diabetes glycaemic control and MACE risk reduction in type 2 diabetes with established cardiovascular disease (SUSTAIN 6). Sourced from a Vietnamese drug-information listing citing the DAV decision, not from the DAV register directly - see review note.
• Food and Drug Administration Philippines (FDA-PH), Department of Health - national medicines regulator; issues Certificates of Product Registration; importer/distributor licensing is a separate track.
• Philippine market status: injectable semaglutide FDA-PH registered 2022 for type 2 diabetes; weight-management semaglutide reported to have entered the market in late 2025 following local regulatory approval; tirzepatide reported present in select tertiary hospital pharmacies and specialty clinics; all reported as prescription-only; PhilHealth does not cover GLP-1s for weight management. (Philippine public-health sector analysis, June 2026, citing domestic press reporting.)
• Philippine obesity and diabetes burden: Food and Nutrition Research Institute, DOST, 2025 Nutritional Status Updating Survey - 44.5% of adults aged 20–59 obese (39.8% in 2023), NCR 52.7%. Diabetes: approximately 4.3 million diagnosed cases (2021) with a substantial undiagnosed population; projections to the mid-single-digit millions by 2045.
• Indicative Philippine pricing (August 2026): injectable semaglutide for diabetes approx. PHP 7,560 per pen at licensed pharmacies; weight-management semaglutide reported at roughly double the per-unit cost; tirzepatide quoted at approx. PHP 12,000–20,000 per month where carried. All indicative, dated, and subject to the caveats set out in the pricing section.
• World Health Organization, Medical Product Alert N°2/2024: Falsified OZEMPIC (semaglutide), 19 June 2024; WHO Global Surveillance and Monitoring System reports of falsified semaglutide across all regions since 2022, including reports in the Philippines. Cold-chain requirement 2–8°C.
• Regional generics wave, 2026: semaglutide patent expiry in several jurisdictions including India and China, March 2026; Indian generic launches from 21 March 2026 at prices reported up to 70% below originator; India Ministry of Health guidance, April 2026, restricting GLP-1 prescribing to specified specialist categories; commentary flagging spillover risk into Vietnam, the Philippines, Indonesia and Thailand where regulatory capacity varies. (SCMP commentary syndicated via Vietnamese press, April 2026.)